Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
9000 participants
OBSERVATIONAL
2018-11-29
2038-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comprehensive Genomic Profiling Combined With Real Life Data of "The German-Registry of Incidental Gallbladder Carcinoma"
NCT05222854
Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas
NCT05515068
German Adrenocortical Carcinoma Registry
NCT00453674
Registry of the German CLL Study Group
NCT02863692
UNDERSTANDING the RAREST GYNECOLOGICAL CANCERS: a MULTI -OMICS PLATFORM for IMPROVED PATIENTS MANAGEMENT
NCT06582108
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In addition, in a growing amount of patients tumors are diagnosed, whose malignant cells have histological, cytological, or molecular properties of both epithelial tumors ("carcinoma") and mesenchymal tumors ("sarcoma").
Such "mixed" sarcomatoid/epithelial tumors ("CS") are categorized as carcinoma considering their epithelial origin. But in most cases, CS seem to be more aggressive, than other carcinomas with the same origin; often they are characterized by rapid growth, invasion, disease recurrence and metastases.
Due to the rarity of CS, only limited information is available about their clinical course and best therapeutic approaches. Because of these uncertainties and the sarcoma-component of the tumors, several CS-patients are referred to sarcomacenters. As many experiences with single CS-cases as possible should be collected and evaluated to better understand the different CS-forms.
Due to the complexity of diagnosis and therapy of sarcomas and of CS it is of high relevance to depict the current treatment landscape and the effects and course of different treatment options to illuminate the best option for each specific patient. This is compassed by this registry, as it aims to collect information and data on treatment and outcome of most of future German sarcoma cases along with retrospective data collection to achieve a most comprehensive data set as well as the possibility to identify alterations / trends in the procedures used for sarcoma diagnosis and therapy over time.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with bone or soft tissue sarcomas or carcinosarcomas
Adults ≥18 years, verified for bone or soft tissue sarcomas including bone and soft tissue tumors with borderline histological results or with unclear histological dignity (like giant cell tumors of the bone \[GCTB\], desmoid tumors, atypical lipomatous tumors) as well as carcinosarcomas - independent of kind of therapy and therapy line. Thus, the registry is open for all subtypes of sarcomas and CS.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed informed consent form or equivalent (s. chapter 10)
* Age ≥18 years
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Salah-Eddin Al-Batran, Prof. Dr
Role: STUDY_DIRECTOR
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitätsklinikum Tübingen
Tübingen, Baden-Wurttemberg, Germany
Universitätsklinikum Erlangen
Erlangen, Bavaria, Germany
HELIOS Klinikum Bad Saarow
Bad Saarow, , Germany
HELIOS Klinikum Berlin-Buch
Berlin, , Germany
Vivantes Klinikum Berlin-Spandau
Berlin-Spandau, , Germany
Universitätsklinikum Erlangen
Erlangen, , Germany
Klinikum Frankfurt Höchst
Frankfurt, , Germany
Krankenhaus Nordwest KHNW
Frankfurt, , Germany
Uniklinik Freiburg
Freiburg im Breisgau, , Germany
Universitätsmedizin Göttingen
Göttingen, , Germany
Universitätsmedizin Greifswald
Greifswald, , Germany
University Hospital Halle (Saale)
Halle, , Germany
Asklepios Klinik St. Georg
Hamburg, , Germany
Uniklinikum Leipzig
Leipzig, , Germany
Universitätsmedizin Mainz
Mainz, , Germany
Chirurgische Universitätsklinik Mannheim
Mannheim, , Germany
Westfälische Wilhelms-Universität Münster
Münster, , Germany
Klinikum Nürnberg
Nuremberg, , Germany
Barmherzige Brüder Regensburg
Regensburg, , Germany
Uniklinikum Regensburg
Regensburg, , Germany
Universitätsklinikum Würzburg
Würzburg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Christoph K. W. Deinzer, Dr.
Role: primary
Gabriele Jany
Role: backup
Norbert Meidenbauer, Dr.
Role: primary
Sarah Endres
Role: backup
Daniel Pink, Dr. med.
Role: primary
Peter Reichardt, Dr. med.
Role: primary
Annegret Kunitz, Dr.
Role: primary
Norbert Meidenbauer, Dr.
Role: primary
Prof. Dr. Hans Guenter Derigs, Prof.
Role: primary
Thorsten Götze, Prof.
Role: primary
Simone Hettmer, Dr.
Role: primary
Florian Bösch, Dr.
Role: primary
Christian Schmidt, Prof.
Role: primary
Christine Dierks, Prof.
Role: primary
Carolin Tonus, Prof. Dr.
Role: primary
Magdalena Karimi
Role: backup
Dirk Forstmeyer, Dr.
Role: primary
Marius Fried, Dr.
Role: primary
Bernd Kasper, Prof.
Role: primary
Torsten Kessler, Dr.
Role: primary
Marinela Augustin, Dr. med.
Role: primary
Nadia Maguire, Dr.
Role: primary
Matthias Grube, Dr.
Role: primary
Martin Kortüm
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GISAR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.